ATE74510T1 - Adoptivimmuntherapie als behandlungsmodalitaet bei menschen. - Google Patents

Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.

Info

Publication number
ATE74510T1
ATE74510T1 AT86401770T AT86401770T ATE74510T1 AT E74510 T1 ATE74510 T1 AT E74510T1 AT 86401770 T AT86401770 T AT 86401770T AT 86401770 T AT86401770 T AT 86401770T AT E74510 T1 ATE74510 T1 AT E74510T1
Authority
AT
Austria
Prior art keywords
cells
lak
cancer
patients
leukaphereses
Prior art date
Application number
AT86401770T
Other languages
English (en)
Inventor
Steven A Rosenbert
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE74510T1 publication Critical patent/ATE74510T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT86401770T 1985-08-08 1986-08-07 Adoptivimmuntherapie als behandlungsmodalitaet bei menschen. ATE74510T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/763,657 US4690915A (en) 1985-08-08 1985-08-08 Adoptive immunotherapy as a treatment modality in humans
EP86401770A EP0211769B1 (de) 1985-08-08 1986-08-07 Adoptivimmuntherapie als Behandlungsmodalität bei Menschen

Publications (1)

Publication Number Publication Date
ATE74510T1 true ATE74510T1 (de) 1992-04-15

Family

ID=25068444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86401770T ATE74510T1 (de) 1985-08-08 1986-08-07 Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.

Country Status (6)

Country Link
US (1) US4690915A (de)
EP (1) EP0211769B1 (de)
JP (1) JPS62116518A (de)
AT (1) ATE74510T1 (de)
CA (1) CA1297002C (de)
DE (1) DE3684732D1 (de)

Families Citing this family (494)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4883662A (en) * 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US4902288A (en) * 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
EP0302894B1 (de) * 1986-04-28 1992-11-19 Endotronics Inc. Zuchtverfahren für leukocyten
US5002879A (en) * 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US4937194A (en) * 1986-05-12 1990-06-26 Baxter International Inc. Method for metering nutrient media to cell culture containers
US4829002A (en) * 1986-05-12 1989-05-09 Baxter International Inc. System for metering nutrient media to cell culture containers and method
US4971795A (en) * 1986-07-08 1990-11-20 Biomira, Inc. Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
DE3750151T2 (de) * 1986-09-19 1994-12-01 Oncogen Verwendung von aktivierten T-Lymphozyten zur Vorbereitung einer pharmazeutischen Zusammensetzung zur Behandlung von AIDS.
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
EP0331716A4 (de) * 1987-09-22 1990-02-06 Arthur Allen Vandenbark Verfahren zur selektiven modulation der expression und der funktion einer zellulären oberflächendeterminante und auf diese weise produzierte neue menschliche zellen.
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5066489A (en) * 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5278143A (en) * 1988-04-25 1994-01-11 Trustees Of Boston University Prophylactic and therapeutic methods for treating interleukin-mediated edemas
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
GB8826298D0 (en) * 1988-11-10 1988-12-14 Williams N S Production of lak cells compositions containing them & their use in cancer therapy
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US6143508A (en) * 1989-06-29 2000-11-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Device and process for cell capture and recovery
US5108760A (en) * 1989-07-21 1992-04-28 Terumo Corporation Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
JPH05502369A (ja) * 1989-09-14 1993-04-28 セルコ、インコーポレイテッド 養子免疫療法に用いられる生体外増殖リンパ性細胞の製造方法
JPH0728732B2 (ja) * 1990-04-17 1995-04-05 日本石油株式会社 動物細胞増殖促進剤及び無血清培地
US5344755A (en) * 1990-04-21 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
ES2074879T3 (es) * 1991-01-16 1995-09-16 Schering Corp Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
EP0578740A4 (en) * 1991-04-05 1995-12-20 Univ Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
EP2119784A3 (de) * 1991-08-23 2010-07-07 Board Of Regents Of The University Of Nebraska Verfahren und Zusammensetzungen zur Zellenumprogrammierung
CA2127107C (en) * 1991-12-31 2007-06-19 Bruce L. A. Carter Methods and compositions for reducing blood loss
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US5296353A (en) * 1992-04-06 1994-03-22 The United States Of America As Represented By The Department Of Health And Human Services Evaluation and treatment of patients with progessive immunosuppression
US5229109A (en) * 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
US5670352A (en) * 1993-03-18 1997-09-23 Behringwerke Aktiengesellschaft Stable growth transformation of human T-lymphocytes by Herpesvirus saimiri (H. saimiri) subgroup C
ES2204919T3 (es) * 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
CA2196756A1 (en) * 1994-08-08 1996-02-22 Jan Urban Kristoffer Hellstrand Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
DE69519521T2 (de) * 1994-10-03 2001-06-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5935847A (en) * 1994-10-28 1999-08-10 Baxter International Inc. Multilayer gas-permeable container for the culture of adherent and non-adherent cells
US6297046B1 (en) 1994-10-28 2001-10-02 Baxter International Inc. Multilayer gas-permeable container for the culture of adherent and non-adherent cells
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6391404B1 (en) 1995-06-07 2002-05-21 Baxter International Inc. Coextruded multilayer film materials and containers made therefrom
US6024220A (en) * 1995-06-07 2000-02-15 Baxter International Inc. Encapsulated seam for multilayer materials
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
EP0979101B1 (de) 1996-07-03 2010-10-27 Merial, Inc. Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
US6884414B1 (en) * 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO1999042121A1 (en) * 1998-02-20 1999-08-26 University Of Miami Modified heat shock protein-antigenic peptide complex
AP1261A (en) 1998-02-24 2004-03-19 Sisters Of Providence In Oregon Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response.
US6790604B1 (en) 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
DE69940774D1 (de) 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6929791B2 (en) 1998-07-16 2005-08-16 Institut Pasteur Peptides of IL-2 and derivatives thereof
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
CA2345277C (en) 1998-10-20 2011-05-24 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP1268763A2 (de) * 2000-03-28 2003-01-02 University Of Rochester Verfahren zur herstellung einer bibliothek und zur selektion von polynukleotiden
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
EP1286693A4 (de) 2000-06-02 2005-07-13 Univ Connecticut Health Ct Komplexe aus alpha-2-makroglobulin und antigenen molekülen zur immuntherapie
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
AU2001216472A1 (en) * 2000-11-30 2002-06-11 Imperial College Innovations Limited Immunotherapeutic methods and molecules
WO2002046416A2 (en) 2000-12-04 2002-06-13 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
CN1635896A (zh) * 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
CN1628167A (zh) * 2001-11-22 2005-06-15 医学基因公司 白细胞介素－2基因转移的淋巴因子活化的杀伤细胞
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US8034334B2 (en) * 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US9809654B2 (en) * 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2514500A1 (en) * 2003-02-20 2004-09-10 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
CA2538794C (en) * 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1697399B1 (de) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
US20090162374A1 (en) * 2005-09-14 2009-06-25 Geraghty Daniel E Specific removal of activated immune cells
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2643337C (en) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
EP2155241A4 (de) * 2007-05-04 2010-06-02 Boris Skurkovich Verhinderung von krebs durch immunisierung
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009097119A2 (en) 2008-01-29 2009-08-06 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
JP2011515399A (ja) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ 熱ショックタンパクｇｐ９６ワクチン接種及びそれを用いた方法
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
EP2341929B1 (de) 2008-10-06 2017-01-25 University Of Chicago Zusammensetzungen und verfahren im zusammenhang mit bakteriellen emp proteinen
AU2009316371B2 (en) * 2008-11-21 2014-02-20 University Of Miami HIV/SIV vaccines for the generation of mucosal and systemic immunity
CN102325875B (zh) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
EP2427485B1 (de) * 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133-epitope
CA2772551A1 (en) 2009-08-26 2011-03-03 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
EP2569633B1 (de) 2010-05-14 2016-02-10 The General Hospital Corporation Zusammensetzungen und verfahren zur identifikation tumorspezifischer neoantigene
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
MX2013004792A (es) 2010-10-27 2013-08-27 Baylor College Medicine Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112013032421A2 (pt) 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
EP2755679B1 (de) 2011-09-13 2017-08-02 Immunotope, Inc. Zytotoxische t-lymphozyten-induzierende immunogene zur prävention, behandlung und diagnose von krebs
EP3326467B1 (de) 2011-09-16 2020-03-11 Baylor College of Medicine Gegen die tumormikroumgebung gerichtete manipulierte nkt-zellen
BR112014007676A2 (pt) 2011-09-30 2017-04-18 The Univ Of Miami células-tronco renais isoladas do rim
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
EP4282419A1 (de) 2012-12-20 2023-11-29 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
EP2983702A2 (de) 2013-04-07 2016-02-17 The Broad Institute, Inc. Zusammensetzungen und verfahren für personalisierte neoplasieimpfstoffe
EP3783098A1 (de) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
CA2945388A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
KR20200138445A (ko) 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
ES2987570T3 (es) 2014-11-05 2024-11-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
ES2819553T3 (es) 2014-12-03 2021-04-16 Juno Therapeutics Inc Métodos y composiciones para terapia celular adoptiva
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
KR102615825B1 (ko) 2015-03-11 2023-12-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전위효소 폴리펩타이드 및 이의 용도
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
HK1255161A1 (zh) 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
US20190119350A1 (en) 2015-09-09 2019-04-25 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
WO2017046335A1 (en) 2015-09-18 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
JP6955487B2 (ja) 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
US10588986B2 (en) 2015-09-28 2020-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3365453A2 (de) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Verfahren, kits, mittel und vorrichtungen zur transduktion
EP3368075B1 (de) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimärische antigennrezeptoren (cars) und ihre verwendungen
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
BR112018008442A2 (pt) 2015-11-05 2018-11-06 Juno Therapeutics Inc receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
EP4212547A1 (de) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modifizierte chimäre rezeptoren und zugehörige zusammensetzungen und verfahren
EP4212166A1 (de) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Zusammensetzungen und verfahren zur verminderung von immunantworten gegen zelltherapien
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
WO2017161212A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
EP3430548A1 (de) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Verfahren zur bestimmung der dosierung eines therapeutikums und verwandte behandlungen
MX2018011480A (es) 2016-03-22 2019-03-28 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Metodos de intervencion temprana para prevenir o aminorar toxicidad.
EP3439675A4 (de) 2016-04-08 2019-12-18 Purdue Research Foundation Verfahren und zusammensetzungen für car-t-zelltherapie
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US20190136230A1 (en) 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
EP4011381A1 (de) 2016-06-03 2022-06-15 Memorial Sloan-Kettering Cancer Center Adoptive zelltherapien als frühe behandlungsoptionen
CA3024725A1 (en) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
EP3475706B1 (de) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
EP3269739A1 (de) 2016-07-15 2018-01-17 OGD2 Pharma Humanisierter antikörper gegen o-acetyliertes gd2-gangliosid (oacgd2)
US12304935B2 (en) 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
ES3041722T3 (en) 2016-07-29 2025-11-14 Inst Nat Sante Rech Med Antibodies targeting tumor associated macrophages and uses thereof
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
MX2019003768A (es) 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
JP7623784B2 (ja) 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
JP2019532997A (ja) 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｂｔｋ阻害剤との併用療法
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
BR112019011065A2 (pt) 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
KR20190098747A (ko) 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
MX2019008227A (es) 2017-01-10 2020-08-17 Juno Therapeutics Inc Analisis epigenetico de terapia celular y metodos relacionados.
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP3385373A1 (de) 2017-04-05 2018-10-10 Centro de Neurociências e Biologia Celular Zusammensetzungen zur umprogrammierung von zellen in dendritischen zellen oder antigen-präsentierende zellen, verfahren und verwendungen davon
WO2018185709A1 (en) 2017-04-05 2018-10-11 Centro De Neurociencias E Biologia Celular Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
CN118948892A (zh) 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
MA48781A (fr) 2017-06-02 2020-04-08 Juno Therapeutics Inc Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
BR112019027133B8 (pt) 2017-06-20 2022-08-09 Inst Curie Uso de uma célula imune modificada deficiente para suv39h1
EA202090149A1 (ru) 2017-06-28 2020-05-31 Ридженерон Фармасьютикалз, Инк. Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
TWI832820B (zh) 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
EP3664835B1 (de) 2017-08-09 2024-10-23 Juno Therapeutics, Inc. Verfahren und zusammensetzungen zur herstellung genetisch veränderter zellen
KR20250016455A (ko) 2017-08-09 2025-02-03 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
WO2019054865A1 (en) 2017-09-14 2019-03-21 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell based immunotherapy
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
EP3704229B1 (de) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Verfahren zur herstellung einer t-zell-zusammensetzung
WO2019089884A2 (en) 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3707258A1 (de) 2017-11-06 2020-09-16 Editas Medicine, Inc. Verfahren, zusammensetzungen und komponenten zum crispr-cas9-editing von cblb in t-zellen zur immuntherapie
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
JP7271539B2 (ja) 2017-11-14 2023-05-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル リンホトキシンアルファ遺伝子について遺伝的に改変された調節性ｔ細胞及びその使用
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
US12161670B2 (en) 2017-12-08 2024-12-10 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
EP3737765B2 (de) 2018-01-12 2025-01-22 Curocell Inc. Verbesserte immunzellen unter verwendung von dualer shrna und zusammensetzung damit
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
JP7383620B2 (ja) 2018-01-31 2023-11-20 セルジーン コーポレイション 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
EP3749685A4 (de) 2018-02-09 2021-12-22 National University of Singapore Aktivierung von chimären nkg2d-rezeptoren und verwendungen davon in der immuntherapie mit natürlichen killerzellen
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
EP3755347B1 (de) 2018-02-21 2025-06-25 Board of Regents, The University of Texas System Universelle antigen-präsentierende zellen und verwendungen davon
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
EP3762012A1 (de) 2018-03-09 2021-01-13 Ospedale San Raffaele S.r.l. Il-1-antagonist und durch zelltherapie induzierte toxizität
EP3765065A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Von sekretogranin v abgeleitete, antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
WO2019175384A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
US20210023209A1 (en) 2018-03-16 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3773908A1 (de) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T-zell-rezeptoren und gentechnisch veränderte zellen zur expression davon
MA52207A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(ｃａｒ) ｔ세포 요법과 키나제 억제제의 조합요법
CN112839671A (zh) 2018-05-17 2021-05-25 明尼苏达大学董事会 抗药性免疫细胞及其使用方法
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CN112805378A (zh) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 用于评估整合核酸的方法
CA3110089A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
EP3844186A4 (de) 2018-08-29 2022-08-17 National University of Singapore Verfahren zur spezifischen stimulation des überlebens und der expansion von genetisch modifizierten immunzellen
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
WO2020053122A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US11993766B2 (en) 2018-09-21 2024-05-28 Bruker Cellular Analysis, Inc. Functionalized well plate, methods of preparation and use thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
KR20210078526A (ko) 2018-10-18 2021-06-28 버클리 라잇츠, 인크. 원 항원 제시 합성 표면, 활성화된 t 세포, 및 이들의 용도
WO2020086647A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
EP3873937A2 (de) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimäre antigenrezeptoren spezifisch für g-protein-gekoppelte rezeptoren klasse c, gruppe 5, element d (gprc5d)
ES2968737T3 (es) 2018-11-06 2024-05-13 Juno Therapeutics Inc Proceso para producir células T manipuladas genéticamente
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
IL283218B2 (en) 2018-11-16 2025-11-01 Juno Therapeutics Inc Dosing methods of engineered T cells for the treatment of malignant B cells
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
CN113692285A (zh) 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
MX2021008739A (es) 2019-01-24 2021-10-13 Valorisation Hsj Lp Secuencias reguladoras de la transcripción específicas de células y usos de estas.
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3773918A4 (de) 2019-03-05 2022-01-05 Nkarta, Inc. Cd19-gerichtete chimäre antigenrezeptoren und deren verwendungen in der immuntherapie
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
EP3983537A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
WO2021007180A1 (en) 2019-07-05 2021-01-14 Case Western Reserve University Priming media and methods for stem cell culture and therapy
EP3999540A1 (de) 2019-07-16 2022-05-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifizität für cd38 und verwendungen davon
BR112022001148A2 (pt) 2019-07-23 2022-03-15 Inst Nat Sante Rech Med Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
EP4004049A1 (de) 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimäre antigenrezeptoren mit mage-a4-spezifität und ihre verwendungen
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
JP2022552270A (ja) 2019-10-09 2022-12-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 変異ｃｘｃｒ４を発現するように改変された又は部分的に欠失されたｔ細胞及びその使用
CA3154281A1 (en) 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
US20220387493A1 (en) 2019-11-06 2022-12-08 Baylor College Of Medicine Method for producing cytotoxic effector memory t-cells for car t-cell treatment of cancer
IL292667B1 (en) 2019-11-07 2026-02-01 Juno Therapeutics Inc Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione
KR20220105161A (ko) 2019-11-25 2022-07-26 아스가르드 테라퓨틱스 아베 항원 제시를 위해 세포를 2형 수지상 세포 성분으로 재프로그래밍하기 위한 조성물, 그 방법 및 용도
MX2022006715A (es) 2019-12-06 2022-09-23 Juno Therapeutics Inc Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b.
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
WO2021142376A1 (en) 2020-01-08 2021-07-15 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
EP4093433A1 (de) 2020-01-24 2022-11-30 Juno Therapeutics, Inc. Verfahren zum dosieren und zur behandlung von follikulären lymphomen und rangenzonen-lymphomen im rahmen der adaptiven zelltherapie
EP4093753A1 (de) 2020-01-24 2022-11-30 Regeneron Pharmaceuticals, Inc. Bevorzugt exprimierte antigene in melanomen (prame) t-zell-rezeptoren und verfahren zur verwendung davon
JP2023512209A (ja) 2020-01-28 2023-03-24 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞形質導入のための方法
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
EP4110823A1 (de) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
CN115916963A (zh) 2020-03-27 2023-04-04 门德斯有限公司 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
US20230165872A1 (en) 2020-04-28 2023-06-01 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
KR20230025662A (ko) 2020-05-05 2023-02-22 리제너론 파마슈티칼스 인코포레이티드 Cd28 제타 및 cd3 제타를 포함하는 car
CA3180683A1 (en) 2020-05-12 2021-11-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
CN115715295A (zh) 2020-05-27 2023-02-24 安逊生物科学股份有限公司 将car t细胞重新定向到感兴趣的抗原的衔接分子
KR20230025005A (ko) 2020-06-17 2023-02-21 얀센 바이오테크 인코포레이티드 만능 줄기세포의 제조를 위한 재료 및 방법
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
EP4171617A1 (de) 2020-06-30 2023-05-03 Mendus B.V. Verwendung von zellen aus leukämie in eierstockkrebsimpfstoffen
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
WO2022015955A1 (en) 2020-07-16 2022-01-20 Umoja Biopharma, Inc. Gated adapter targeting receptor
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
EP4188395A1 (de) 2020-07-30 2023-06-07 Institut Curie Socs1-deffiziente immunzellen
EP4189071A1 (de) 2020-08-03 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Population von treg-zellen, die funktionell mit einer regulatorischen aktivität behaftet sind, und ihre verwendung zur adoptiven therapie
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
WO2022040444A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022036458A1 (en) 2020-08-21 2022-02-24 12343096 Canada Inc. Modular assembly receptors and uses thereof
EP4204546A1 (de) 2020-08-31 2023-07-05 City of Hope Neue zelllinien, verfahren zur herstellung natürlicher killerzellen und verwendungen davon
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022074098A1 (en) 2020-10-08 2022-04-14 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Method for the identification of cancer neoantigens
EP4240756A1 (de) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Zellen zur expression eines chimären rezeptors aus einem modifizierten invarianten kettenlocus der cd3-immunglobulin-superfamilie und zugehörige polynukleotide und verfahren
CA3196677A1 (en) 2020-11-05 2022-05-12 Erik Hans MANTING Use of tumor-independent antigens in immunotherapies
WO2022112469A1 (en) 2020-11-27 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
JP2024506249A (ja) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法
WO2022161502A1 (zh) 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
WO2022177979A1 (en) 2021-02-16 2022-08-25 A2 Biotherapeutics, Inc. Compositions and methods for treating her2 positive cancers
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
MX2023011370A (es) 2021-03-29 2023-11-24 Juno Therapeutics Inc Combinacion de una terapia con celulas t con receptores de antigenos quimericos (car) y un compuesto inmunomodulador para el tratamiento de linfoma.
CN118201618A (zh) 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
AU2022271212A1 (en) 2021-05-04 2023-11-30 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
US20250304915A1 (en) 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
KR20240042483A (ko) 2021-07-30 2024-04-02 에쓰티 피에이치아이 테라퓨틱스 컴퍼니 리미티드 범용성 t 세포 및 이의 응용
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
KR20240112994A (ko) 2021-11-03 2024-07-19 셀진 코포레이션 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
EP4433512A4 (de) 2021-11-19 2025-12-31 Univ Pennsylvania Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
WO2023139269A1 (en) 2022-01-21 2023-07-27 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
WO2023152633A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
EP4479143A1 (de) 2022-02-18 2024-12-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von tcr-defizienten car-tregs in kombination mit monoklonalen anti-tcr-komplex-antikörpern zur induzierung von dauerhafter toleranz
CA3244604A1 (en) 2022-02-22 2023-08-31 Deka Biosciences, Inc. METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
JP2025508076A (ja) 2022-03-08 2025-03-21 アレンティス・セラピューティクス・アクチェンゲゼルシャフト Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (de) 2022-05-20 2023-11-22 Mnemo Therapeutics Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
EP4532695A1 (de) 2022-05-25 2025-04-09 Celgene Corporation Verfahren zur herstellung von t-zelltherapien
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
EP4543923A1 (de) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Behandlungsverfahren für die zweite therapie von cd19-gezielten car-t-zellen
EP4547230A1 (de) 2022-06-29 2025-05-07 Juno Therapeutics, Inc. Lipidnanopartikel zur abgabe von nukleinsäuren
WO2024019984A1 (en) 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
WO2024044779A2 (en) 2022-08-26 2024-02-29 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
EP4580658A1 (de) 2022-08-31 2025-07-09 Institut National de la Santé et de la Recherche Médicale Verfahren zur erzeugung effizienterer car-t-zellen
EP4583905A1 (de) 2022-09-06 2025-07-16 Institut National de la Santé et de la Recherche Médicale Neuartige car-t-doppelspaltzellen zur behandlung von cd38-positiven hämatologischen malignomen
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
EP4583876A1 (de) 2022-09-08 2025-07-16 Juno Therapeutics, Inc. Kombination einer t-zell-therapie und kontinuierlicher oder intermittierender dgk-hemmerdosierung
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
EP4598565A1 (de) 2022-10-07 2025-08-13 Institut National de la Santé et de la Recherche Médicale Verfahren zur erzeugung verbesserter car-t-zellen
WO2024091944A1 (en) 2022-10-25 2024-05-02 Cargo Therapeutics, Inc. Split receptor switch polypeptides and uses thereof
EP4608854A2 (de) 2022-10-27 2025-09-03 Cargo Therapeutics, Inc. Zusammensetzungen und verfahren für allogene immuntherapien
EP4608856A1 (de) 2022-10-27 2025-09-03 CARGO Therapeutics, Inc. Zusammensetzungen und verfahren für verbesserte immuntherapien
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024123760A1 (en) 2022-12-05 2024-06-13 Cargo Therapeutics, Inc. Multiplex cell selection compositions and uses thereof
KR20250135354A (ko) 2022-12-13 2025-09-12 주노 쎄러퓨티크스 인코퍼레이티드 Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
WO2024168276A2 (en) 2023-02-09 2024-08-15 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies
EP4687959A1 (de) 2023-03-24 2026-02-11 Cornell University Verwendung von t-zellen aus tumordränierenden lymphknoten zur chimären antigenrezeptor(car)-t-zelltherapie zur behandlung von krebs
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024223877A1 (en) 2023-04-26 2024-10-31 Institut National de la Santé et de la Recherche Médicale Method for modulating the differentiation and functions of human dendritic cells
EP4720109A1 (de) 2023-05-25 2026-04-08 Regeneron Pharmaceuticals, Inc. T-zell-rezeptoren, die präsentierte hpv16-, mart1-, cmv-, ebv- oder influenza-peptide binden
WO2025029930A1 (en) 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
WO2025049972A1 (en) 2023-09-01 2025-03-06 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025085680A1 (en) 2023-10-17 2025-04-24 Cargo Therapeutics, Inc. Methods for manufacturing car t cells
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
WO2025090978A1 (en) 2023-10-26 2025-05-01 Cargo Therapeutics, Inc. Modified immune effector cells
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025125363A1 (en) 2023-12-11 2025-06-19 Institut National de la Santé et de la Recherche Médicale Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
WO2025129084A1 (en) 2023-12-13 2025-06-19 Umoja Biopharma, Inc. Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025255030A1 (en) 2024-06-03 2025-12-11 Cornell University Interferon gamma responsive chimeric t cell costimulatory receptor
WO2026002973A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Host immune cells engineered to overexpress a foxk1 polypeptide
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof
WO2026055226A1 (en) 2024-09-03 2026-03-12 Legend Biotech Ireland Limited Cells overexpressing b3gnt2 and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049611B2 (de) * 1980-10-02 1993-12-08 Hooper Trading Co. N.V. T-Zell-Wachstumsfaktor und Verfahren zu seiner Herstellung
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
JPS61500790A (ja) * 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
JPS62263127A (ja) * 1986-05-06 1987-11-16 メレルダウフア−マス−テイカルズ　インコ−ポレ−テツド 自己由来のｌａｋ細胞、インタ−ロイキン−２、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置

Also Published As

Publication number Publication date
EP0211769A2 (de) 1987-02-25
CA1297002C (en) 1992-03-10
DE3684732D1 (de) 1992-05-14
JPS62116518A (ja) 1987-05-28
EP0211769B1 (de) 1992-04-08
EP0211769A3 (en) 1989-03-29
US4690915A (en) 1987-09-01

Similar Documents

Publication Publication Date Title
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
US4789658A (en) Immunoprophylactic and immunotherapeutic agents
US5573764A (en) Use of interleukin-12 to prevent graft versus host disease
Biron et al. Interferon induces natural killer cell blastogenesis in vivo
US5443983A (en) Method of culturing lymphocytes and method of treatment using such lymphocytes
Merluzzi et al. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2.
EP2036569A2 (de) Verfahren zur Behandlung einer Sekundärimmundefizienz
DE3677897D1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
Dawson et al. Lymphokine activated killing of fresh human leukaemias
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
Ishikawa et al. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2
Nakamura et al. Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases
Garaci et al. Enhanced immune response and antitumor immunity with combinations of biological response modifiers
Platsoucas et al. Immunomodulation of human leukocytes by staphylococcal enterotoxin A: augmentation of natural killer cells and induction of suppressor cells
Nagatani et al. A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2)
Marolda et al. A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects
Vitale et al. Cytotoxic effectors activated by low‐dose IL‐2 plus IL‐12 lyse IL‐2‐resistant autologous acute myeloid leukaemia blasts
US5871725A (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Jacobs et al. Lymphokine activateed killer (LAK) cell-mediated lysis of murine glioma: trypsinchymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells
Merluzzi et al. Expansion of Murine Cytotoxic Precursors In Vitro and In Vivo by Purified Interleukin-2
Igarashi et al. Induction of the differentiation of memory T killer cells with factors released from macrophage-like cell lines
Hirashima et al. Induction of an eosinophil chemotactic factor production from T lymphocytes by a B cell lymphoma line

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time